(placeholder)

中文

Crystal Pharmatech, Co is honored to announce it has expanded its’ leadership team to include Dr. Shanming Kuang. This reflects Crystal Pharmatech’s continued strategy to hire the most experienced solid state research scientists with diverse large pharma development experience.  

 

As Vice President, Head of US Research and Development, Dr. Kuang will report directly to the CSO, Yanfeng Zhang, and work closely with the Business Development team to ensure clients are offered the highest level of service in the industry.

 

Before joining Crystal Pharmatech, Dr. Kuang spent a combined 16 years at BMS, Roche, and GSK.  His tenure involved managing solid state chemistry groups involved in integrated drug development teams focusing on form and formulation selection.  His teams were integral in understanding compound developability and ensuring projects were minimally impacted by solid state property issues.

 

“Shanming’s experience is directly aligned with our competitive advantage – experienced drug development scientist who understands the impact of solid state properties and will push for the right amount of work at the right time to ensure the most efficient drug development possible” explains Dr. Alex M. Chen, CEO of Crystal Pharmatech Co., Ltd.  “Focusing on applied problem solving will continue to ensure Crystal Pharmatech remains the leading technology-driven CRO.” 

Crystal Pharmatech, Co is honored to announce it has expanded its’ leadership team to include Dr. Shanming Kuang. This reflects Crystal Pharmatech’s continued strategy to hire the most experienced solid state research scientists with diverse large pharma development experience.